Japanese postmarketing surveillance of erlotinib in unresectable recurrent and advanced non-small cell lung cancer that was aggravated following chemotherapy.

Next Previous
Trial Profile

Japanese postmarketing surveillance of erlotinib in unresectable recurrent and advanced non-small cell lung cancer that was aggravated following chemotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms POLARSTAR
  • Sponsors Chugai Pharmaceutical

    • Most Recent Events

    • 11 Feb 2012 New trial record
    • 01 Oct 2009 Recruitment completed, according to 23rd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top